{"id":4221,"date":"2026-11-11T09:00:00","date_gmt":"2026-11-11T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4221"},"modified":"2026-11-11T20:45:32","modified_gmt":"2026-11-12T00:45:32","slug":"pfizer-and-blackstone-agree-to-fund-berobenatide-development","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4221","title":{"rendered":"Pfizer and Blackstone Agree to Fund Berobenatide Development"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"768\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Pfizer_Blackstone_Deal_and_Financing-768x768.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4228\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Pfizer_Blackstone_Deal_and_Financing-768x768.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Pfizer_Blackstone_Deal_and_Financing-300x300.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Pfizer_Blackstone_Deal_and_Financing-1024x1024.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Pfizer_Blackstone_Deal_and_Financing-150x150.png 150w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Pfizer_Blackstone_Deal_and_Financing.png 1254w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Pfizer; Blackstone Life Sciences<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Development cost-sharing financing (up to $1.5 billion)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Long-acting peptide (monthly GLP-1 receptor agonist)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Berobenatide<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>GLP-1 receptor<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Chronic weight management and related conditions<\/p>\n<h4>Summary<\/h4>\n<p>Pfizer announced November 11 that Blackstone-managed funds will cover up to $1.5 billion of berobenatide development costs through 2028 in exchange for conditional milestone payments. Pfizer retains ownership and operating control.<\/p>\n<p>The arrangement funds an investigational monthly GLP-1 receptor agonist for chronic weight management and related conditions. Blackstone milestones depend on US approval for monthly monotherapy and sales thresholds. The announcement does not say the full $1.5 billion has been paid or that pivotal trials have succeeded.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> risk-sharing may support an expansive Phase 3 program while preserving Pfizer control. Support: committed cost-sharing framework and Pfizer\u2019s stated trial program. Against: contingent payments may transfer substantial future economics.<\/p>\n<p><strong>Interpretation B:<\/strong> external capital may reflect the unusually costly and competitive obesity program. Support: more than ten Phase 3 studies planned or underway. Against: the deal alone does not establish a cash constraint or weak efficacy. Trial results, adverse-event discontinuation, dosing adherence, regulatory feedback, exact economic waterfall and funding drawn will distinguish these views.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Berobenatide is Pfizer\u2019s investigational long-acting GLP-1 receptor agonist peptide. GLP-1 activation reduces appetite and affects glucose regulation; clinical differentiation from existing obesity agents remains to be demonstrated.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Up to $1.5 billion of development costs through 2028, funded by Blackstone against conditional milestones.<\/li>\n<li>Milestones depend on US approval for monthly monotherapy and sales thresholds.<\/li>\n<li>The announcement does not state that the full amount is paid or that pivotal trials succeeded.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>A large risk-sharing structure for a late-stage obesity program. The economics given up and the trial outcomes will determine whether it proves favorable.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: mixed. Confidence in Facts: high. Confidence in Interpretation: moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer announced November 11 that Blackstone-managed funds will cover up to $1.5 billion of berobenatide development costs through 2028 in exchange for conditional milestone payments. Pfizer retains ownership and operating control.<\/p>\n","protected":false},"author":1,"featured_media":4228,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[1451,1450,122],"class_list":["post-4221","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-deals-and-financing","tag-berobenatide","tag-blackstone","tag-pfizer"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4221"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4221\/revisions"}],"predecessor-version":[{"id":4254,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4221\/revisions\/4254"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4228"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}